Mineralocorticoid receptor antagonists,申请号US201214110441-传众专利搜索

Mineralocorticoid receptor antagonists

申请公布号：US9487506(B2)

申请号：US201214110441

申请日期：2012.04.11

申请公布日期：2016.11.08

申请人：

Merck Sharp & Dohme Corp.

发明人：Lan Ping;Liu Kun;Ogawa Anthony;Shen Hong;Yang Christine;Wang Yuguang;Beresis Richard;Qi Changhe

分类号：C07D413/06;A61K31/4245;C07D401/04;A61K31/4439;C07D231/56;A61K31/416

主分类号：C07D413/06

代理人：Shatynski Patricia A.;Fitch Catherine D.

地址：Rahway NJ US

摘要：Compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the Formula (I), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the Formula (I) are disclosed.;

主权项：1. A compound selected from 3-(4-Chloro-2-fluorobenzyl)-1H-indazole and 3-(4-Chloro-2-fluorobenzyl)-7-ethyl-1H-indazole; N-{3-[1-(4-Chloro-2-fluorophenyl)-3-cyanopropyl]-1H-indazol-7-yl}methanesulfonamide; 4-(4-Chloro-2-fluorophenyl)-4-(7-pyridin-3-yl-1H-indazol-3-yl)butanenitrile; 4-(4-Chloro-2-fluorophenyl)-4-(7-pyridin-4-yl-1H-indazol-3-yl)butanenitrile; N-{3-[1-(4-Chloro-2-fluorophenyl)-4-hydroxybutyl]-1H-indazol-7-yl}methanesulfonamide; N-{3-[1-(4-Chloro-2-fluorophenyl)-2-cyanoethyl]-1H-indazol-7-yl}methanesulfonamide; N-{3-[1-(4-Chloro-2-fluorophenyl)-3-cyanopropyl]-1H-indazol-7-yl}cyclopropanesulfonamide; N-{3-[1-(4-Chloro-2-fluorophenyl)-3-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-1H-indazol-7-yl}methanesulfonamide; N-{3-[1-(4-Chloro-2-fluorophenyl)-4-oxopentyl]-1H-indazol-7-yl}methanesulfonamide; N-{3-[1-(4-Chloro-2-fluorophenyl)-4-hydroxy-4-methylpentyl]-1H-indazol-7-yl}methanesulfonamide; N-{3-[1-(4-Chloro-2-fluorophenyl)-4-hydroxy-4-ethylhexyl]-1H-indazol-7-yl}methanesulfonamide; 4-(4-Chloro-2-fluorophenyl)-4-(1H-indazol-3-yl)butanenitrile; 4-(4-Chloro-2-fluorophenyl)-4-(1-methyl-1H-indazol-3-yl)butanenitrile; 4-(4-Chloro-2-fluorophenyl)-4-(1-ethyl-1H-indazol-3-yl)butanenitrile; 4-(4-Chloro-2-fluorophenyl)-4-(1-propyl-1H-indazol-3-yl)butanenitrile; 4-(1-Benzyl-1H-indazol-3-yl)-4-(4-chloro-2-fluorophenyl)butanenitrile; Methyl {3-[1-(4-chloro-2-fluorophenyl)-3-cyanopropyl]-1H-indazol-1-yl}acetate; tert-Butyl {3-[1-(4-chloro-2-fluorophenyl)-3-cyanopropyl]-1H-indazol-1-yl}acetate; Methyl 3-{3-[1-(4-chloro-2-fluorophenyl)-3-cyanopropyl]-1H-indazol-1-yl}propanoate; 4-(4-Chloro-2-fluorophenyl)-4-{1-[(methylsulfanyl)methyl]-1H-indazol-3-yl}butanenitrile; 4-(4-Chloro-2-fluorophenyl)-4-[1-(cyanomethyl)-1H-indazol-3-yl]butanenitrile; 4-(4-Chloro-2-fluorophenyl)-4-[1-(2-methoxyethyl)-1H-indazol-3-yl]butanenitrile; tert-Butyl {3-[1-(4-chlorophenyl)-1-methylethyl]-1H-indazol-1-yl}acetate; Methyl {3-[1-(4-chlorophenyl)-1-ethylpropyl]-1H-indazol-1-yl}acetate; Methyl [3-(4-chlorobenzyl)-1H-indazol-1-yl]acetate; and 3-(4-Chlorobenzyl)-1-benzyl-1H-indazole;or a pharmaceutically acceptable salt thereof.